FAME‐04: A Phase 1 trial to assess the safety, acceptability, pharmacokinetics and pharmacodynamics of film and gel formulations of tenofovir
Open Access
- 13 August 2018
- journal article
- research article
- Published by Wiley in Journal of the International AIDS Society
- Vol. 21 (8), e25156
- https://doi.org/10.1002/jia2.25156
Abstract
Introduction Fast‐dissolving vaginal film formulations release antiretroviral drugs directly into vaginal fluid and may be as efficient at drug delivery yet more acceptable to women than gels. In this Phase 1 vaginal film study, the safety, acceptability, pharmacokinetics and pharmacodynamics of two doses of tenofovir (TFV) film and TFV 1% gel were compared to corresponding placebo formulations. Methods Seventy‐eight healthy HIV negative women were randomized to self‐insert daily vaginal film (10 mg TFV, 40 mg TFV or placebo) or 4 mL of vaginal gel (TFV 1% [40 mg] or placebo) for seven days. Grade 2 and higher adverse events (AEs) related to study product were compared across study arms using Fisher's exact test. Plasma TFV concentrations were measured before and 2 hours after last product use. Paired cervical and vaginal tissue biopsies obtained 2 hours after the last dose were measured to determine tenofovir diphosphate (TFV‐DP) concentrations and exposed to HIV in an ex vivo challenge assay. Acceptability was assessed through questionnaire. Results There was only one grade 2 or higher related AE, the primary endpoint; it occurred in the placebo gel arm. AEs occurred in 90% of participants; the majority (91%) were grade 1. AEs were similar across study arms. TFV concentrations in plasma and TFV‐DP concentrations in cervical and vaginal tissues were comparable between 40 mg TFV film and the TFV gel groups. There was a significant relationship between reduced viral replication and TFV‐DP concentrations in cervical tissues. Film users were less likely to report product leakage than gel users (66% vs. 100%, p < 0.001). Conclusions Films were safe and well tolerated. Furthermore, films delivered TFV to mucosal tissues at concentrations similar to gel and were sufficient to block HIV infection of genital tissue ex vivo.Keywords
Funding Information
- National Institutes of Health (AI082639, UL1 TR000005)
- Department of Health and Human Services, State Government of Victoria (HHSN272200800014C)
This publication has 23 references indexed in Scilit:
- Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066)AIDS Research and Human Retroviruses, 2016
- Pharmacological Measures of Treatment Adherence and Risk of HIV Infection in the VOICE StudyThe Journal of Infectious Diseases, 2015
- Models for Predicting Effective HIV Chemoprevention in WomenJAIDS Journal of Acquired Immune Deficiency Syndromes, 2015
- Trial participation disclosure and gel use behavior in the CAPRISA 004 tenofovir gel trialAIDS Care, 2014
- Disclosure of Microbicide Gel Use to Sexual Partners: Influence on Adherence in the CAPRISA 004 TrialAIDS and Behavior, 2014
- Short Communication: Expression of Transporters and Metabolizing Enzymes in the Female Lower Genital Tract: Implications for Microbicide ResearchAIDS Research and Human Retroviruses, 2013
- HIV-1 Infection of Female Genital Tract Tissue for Use in Prevention StudiesJAIDS Journal of Acquired Immune Deficiency Syndromes, 2013
- Use of modern contraception increases when more methods become available: analysis of evidence from 1982–2009Global Health: Science and Practice, 2013
- Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and WomenNew England Journal of Medicine, 2012
- Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in WomenScience, 2010